Janssen signs $847m lung cancer immunotherapy deal with Aduro

Janssen has signed its second deal with California's Aduro BioTech, this time paying $30m upfront and agreeing to milestone payments of up to $817m for rights to lung cancer products developed using Aduro's immunotherapy platform.